

FACSIMILE TRANSMISSION RECORD / COVER SHEET

TO

Name Examiner G. Krishnan
Company or Firm U.S. Patent Office
Facsimile Tel. No. 1-571-273-0654

FROM
PEARNE & GORDON LLP
1801 E. 9th Street, Suite 1200
Cleveland, Ohio 44114-3108
(216)579-1700

Name of Sender Paul A. Serbinowski

COMMENTS

Date August 30, 2005 Cleveland Time 3:16 pm
For 6 page(s), including cover sheet
Client S&P File No. 33944

This transmission was sent from
(216) 579-6073

If you have any problem with your reception please

telephone us at (216) 579-1700 and ask for Amanda Wittine

The documents accompanying this facsimile transmission contain information from the law firm of Pearne & Gordon LLP which may be confidential or privileged. The information is intended to be for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, any disclosure, copying, distribution or use of the contents of this transmitted information is prohibited. If you have received this transmission in error, please notify us by telephone immediately so that we can arrange for the retrieval of the original documents at no cost to you.

Re: U.S. PCT-based Patent Application for
FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL INSTRUMENTS
AND DRUGS BY USING THE SAME
Serial No.: 09/937,991
Filed: January 23, 2002
Atty. Docket No.: 33944

Attachments: - **Courtesy copy of Second Supplemental Amendment (5 pages)**

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hirofumi Yura et al.
Serial No.: 09/937,991
Filing Date: January 23, 2002
Title: "FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL INSTRUMENTS AND DRUGS BY USING THE SAME"
Docket No.: S&P.33944
Examiner: G. Krishnan

**TRANSMITTED VIA FACSIMILE TO: (571) 273-8300
(COURTESY COPY TO EXAMINER KRISHNAN AT (571) 273-0654)**

SECOND SUPPLEMENTAL AMENDMENT

Further to the Supplemental Amendment filed on August 24, 2005, please amend the above-identified application as follows:

(A) Introductory Comments:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper. Remarks begin on page 5 of this paper.